ロード中...
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anti-cancer drug development. Wild-type BRAF and a variety of oncogenic BRAF mutants are dependent on dimerization of the kinase domain, w...
保存先:
| 出版年: | ACS Chem Biol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6733264/ https://ncbi.nlm.nih.gov/pubmed/31243962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00191 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|